Hangzhou AGS MedTech Co. Ltd. A (688581) - Total Liabilities
Based on the latest financial reports, Hangzhou AGS MedTech Co. Ltd. A (688581) has total liabilities worth CN¥127.24 Million CNY (≈ $18.62 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Hangzhou AGS MedTech Co. Ltd. A (688581) equity growth momentum to track the company's year-over-year net asset growth rate.
Hangzhou AGS MedTech Co. Ltd. A - Total Liabilities Trend (2021–2025)
This chart illustrates how Hangzhou AGS MedTech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Hangzhou AGS MedTech Co. Ltd. A generate to measure how efficiently the company converts operating cash flow to free cash.
Hangzhou AGS MedTech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Hangzhou AGS MedTech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
China | CN¥8.92 Billion |
|
NorthIsle Copper and Gold Inc
V:NCX
|
Canada | CA$5.30 Million |
|
Granite Ridge Resources Inc
NYSE:GRNT
|
USA | $484.65 Million |
|
Alpargatas S.A
SA:ALPA3
|
Brazil | R$2.83 Billion |
|
Lotte Chilsung Beverage
KO:005300
|
Korea | ₩2.66 Trillion |
|
Franklin BSP Realty Trust Inc
NYSE:FBRT
|
USA | $4.82 Billion |
|
Interfor Corp
TO:IFP
|
Canada | CA$1.56 Billion |
|
Beijing Navigation Control Technology Co. Ltd.
SHG:688282
|
China | CN¥227.23 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Hangzhou AGS MedTech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Hangzhou AGS MedTech Co. Ltd. A.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou AGS MedTech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
The table below shows the annual total liabilities of Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥160.37 Million ≈ $23.47 Million |
+5.05% |
| 2024-12-31 | CN¥152.67 Million ≈ $22.34 Million |
+24.29% |
| 2023-12-31 | CN¥122.83 Million ≈ $17.97 Million |
+34.11% |
| 2022-12-31 | CN¥91.59 Million ≈ $13.40 Million |
+29.83% |
| 2021-12-31 | CN¥70.55 Million ≈ $10.32 Million |
-- |
About Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic instruments in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; an… Read more